Wall Street analysts expect NewLink Genetics Corp (NASDAQ:NLNK) to announce $5.78 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for NewLink Genetics’ earnings, with the highest sales estimate coming in at $7.35 million and the lowest estimate coming in at $5.00 million. NewLink Genetics posted sales of $2.76 million during the same quarter last year, which suggests a positive year-over-year growth rate of 109.4%. The company is scheduled to issue its next earnings results on Thursday, May 3rd.
On average, analysts expect that NewLink Genetics will report full year sales of $5.78 million for the current fiscal year, with estimates ranging from $18.10 million to $20.00 million. For the next financial year, analysts anticipate that the business will report sales of $11.37 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow NewLink Genetics.
Several equities analysts recently commented on NLNK shares. Zacks Investment Research raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $26.00 price target on shares of NewLink Genetics and gave the stock a “buy” rating in a research report on Monday, January 8th. BidaskClub raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Bank of America dropped their price target on shares of NewLink Genetics from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, March 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $21.00 price target (down previously from $25.00) on shares of NewLink Genetics in a research report on Friday, March 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $21.57.
NewLink Genetics (NASDAQ:NLNK) opened at $8.12 on Wednesday. The firm has a market cap of $314.87, a P/E ratio of -3.46 and a beta of 1.25. NewLink Genetics has a 52-week low of $5.90 and a 52-week high of $25.17.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.